Posted in

10 Leading Fidx Reagents for Hormone Suppliers in China 2026

Brief Introduction to Fidx Reagents for Hormone

Fidx reagents for hormones refer to a specialized category of diagnostic reagents designed for the detection, quantification, and analysis of hormone levels in biological samples, such as blood, serum, urine, and tissue extracts. These reagents leverage advanced molecular biology, immunology, and analytical chemistry technologies to enable accurate, sensitive, and reliable measurement of various hormones—including thyroid hormones, reproductive hormones, pituitary hormones, and metabolic hormones—critical for clinical diagnosis, treatment monitoring, and research applications. In China’s rapidly expanding in vitro diagnostic (IVD) market, Fidx reagents for hormones have emerged as a key segment, supporting healthcare facilities, pharmaceutical R&D institutions, and life science research centers. As demand for precise hormone testing grows amid an aging population, rising chronic disease prevalence, and advances in personalized medicine, leading suppliers in China are investing heavily in R&D, quality control, and global compliance to meet both domestic and international market needs. Below are the 10 leading Fidx reagents for hormone suppliers in China for 2026, with detailed profiles and their core strengths. Fidx Reagents for Hormone


1. Shanghai GlinX Biotechnology Co., Ltd.

Company Introduction
Shanghai GlinX Biotechnology Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and distribution of Fidx reagents for hormones, headquartered in Shanghai’s Zhangjiang High-Tech Park—China’s national innovation hub for life sciences. Founded in 2012, GlinX has built a robust R&D team with over 150 scientists, including experts in immunodiagnostics, molecular biology, and regulatory affairs, holding more than 80 patents related to Fidx reagent technology. The company’s core focus is on developing high-sensitivity Fidx reagents for a wide range of hormone tests, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), progesterone, and insulin. GlinX operates a 10,000-square-meter GMP-compliant production facility, equipped with automated liquid handling systems and advanced quality control laboratories, adhering to ISO 13485 and CFDA (now NMPA) standards. Over the past decade, the company has established a strong distribution network covering 31 provinces in China, with partnerships with over 2,000 hospitals and clinical laboratories. Internationally, GlinX has expanded to Southeast Asia, Europe, and North America, with CE marking and FDA 510(k) clearance for several key Fidx hormone reagents. The company invests 25% of its annual revenue in R&D, launching 5–8 new Fidx hormone products each year to address unmet clinical needs, such as early detection of thyroid disorders and fertility-related hormone imbalances. GlinX also collaborates with top Chinese medical universities, including Fudan University and Shanghai Jiao Tong University, to advance clinical research on hormone-related diseases, ensuring its products align with global clinical standards.
Official Website: https://www.glinx-lab.com/

Features and Advantages:

  • Core Focus: Specializes in high-sensitivity Fidx reagents for 20+ hormone types, with a detection limit up to 0.001 mIU/mL, suitable for both routine clinical testing and research applications.
  • R&D Strength: 25% annual revenue allocated to R&D, 150+ in-house scientists, and long-term partnerships with 5 top medical universities in China, driving 6–8 new product launches annually.
  • Quality Compliance: ISO 13485, NMPA, CE, and FDA 510(k) certifications, with a GMP production facility ensuring batch consistency and reliability.
  • Distribution Network: Covers 31 Chinese provinces, 2,000+ domestic hospitals, and exports to 15+ countries, with local technical support teams in key regions.
  • Customization: Offers tailored Fidx reagent formulations for specific clinical needs, such as pediatric hormone testing and low-level hormone detection for fertility clinics.

2. Kinghawk Pharmaceutical Co., Ltd.

Company Introduction
Kinghawk Pharmaceutical Co., Ltd., a subsidiary of the Beijing-based Kinghawk Group, is a leading IVD reagent manufacturer with over 20 years of experience in hormone diagnostic reagents, including Fidx reagents for hormone analysis. Established in 2001, Kinghawk has its headquarters in Beijing’s Economic and Technological Development Zone, with a production base in Tianjin spanning 50,000 square meters. The company’s Fidx hormone reagent line includes products for thyroid hormones, reproductive hormones, and diabetes-related hormones, with a strong presence in China’s public hospital system. Kinghawk’s R&D center employs over 200 professionals, focusing on improving reagent specificity and reducing cross-reactivity, a key challenge in Fidx hormone testing. The company has obtained NMPA certifications for 45+ hormone reagents, and its products are widely used in China’s tier 2 and tier 3 hospitals, with an annual production capacity of 150 million Fidx reagent kits. Kinghawk also invests in digital diagnostic solutions, integrating its Fidx reagents with automated immunoassay analyzers to streamline clinical workflows. In recent years, the company has expanded its export business to Africa and the Middle East, focusing on affordable, high-quality Fidx hormone reagents for emerging markets. Kinghawk’s commitment to sustainability is reflected in its eco-friendly production processes, reducing reagent waste and energy consumption in its manufacturing facilities.

Features and Advantages:

  • Scale and Affordability: Annual production capacity of 150 million Fidx hormone kits, with competitive pricing, making it a preferred supplier for public hospital networks.
  • Certification Portfolio: 45+ NMPA-certified reagents, plus CE marking, ensuring compliance with both domestic and regional international standards.
  • Integrated Solutions: Fidx reagents compatible with 10+ automated immunoassay analyzers, providing end-to-end testing solutions for clinical labs.
  • Market Reach: Dominates China’s public hospital segment, with 3,000+ institutional clients, and exports to 20+ countries in Africa and the Middle East.
  • Sustainability: Eco-friendly manufacturing processes, with 15% reduction in reagent waste and 20% lower energy use compared to industry averages.

3. Wuhan Huazhong Medical Technology Co., Ltd.

Company Introduction
Wuhan Huazhong Medical Technology Co., Ltd. is a high-tech enterprise specializing in the development of Fidx reagents for hormone testing, located in Wuhan’s Optics Valley, a major life science and tech cluster in Central China. Founded in 2010, the company has a team of 120 R&D staff, including 30 PhDs, with expertise in fluorescence immunoassay technology— the core technology behind Fidx reagents. Huazhong Medical’s Fidx hormone reagents are designed for rapid testing, with results available in 10 minutes, making them ideal for point-of-care testing (POCT) settings, such as clinics and emergency departments. The company’s product line covers 15 hormone types, including cortisol, growth hormone (GH), and prolactin, with a focus on critical care and emergency medicine applications. Huazhong Medical operates a 15,000-square-meter GMP facility, certified by NMPA and ISO 13485, and has invested in advanced fluorescence detection systems to enhance reagent sensitivity. The company has established partnerships with global POCT device manufacturers, integrating its Fidx reagents into portable testing platforms for international markets. In 2025, Huazhong Medical launched a new line of Fidx hormone reagents for home use, targeting consumer demand for at-home hormone testing, with over 500,000 kits sold in the first year. The company also collaborates with the Huazhong University of Science and Technology to advance Fidx technology, focusing on multiplex hormone testing that can detect multiple hormones in a single sample.

Features and Advantages:

  • Rapid Testing: Results in 10 minutes, optimized for POCT settings, with a 99% accuracy rate for 15+ hormone types.
  • Multiplex Technology: Developing Fidx reagents that detect 3–5 hormones in one sample, reducing sample volume and testing time.
  • Home Testing Line: First Chinese supplier to launch FDA-registered at-home Fidx hormone reagent kits, tapping into the consumer healthcare market.
  • R&D Collaboration: Partnership with Huazhong University of Science and Technology, driving innovation in fluorescence immunoassay for hormone detection.
  • Global POCT Integration: Reagents compatible with portable devices, exported to 12 countries for emergency and remote care applications.

4. Sichuan Maccura Biotechnology Co., Ltd.

Company Introduction
Sichuan Maccura Biotechnology Co., Ltd., a subsidiary of the Maccura Group, is a leading IVD manufacturer based in Chengdu, with a comprehensive range of Fidx reagents for hormone testing. Founded in 2003, Maccura has two production bases in Sichuan, totaling 80,000 square meters, and an R&D center with 250 scientists specializing in immunology and clinical chemistry. The company’s Fidx hormone reagent line includes products for thyroid, reproductive, and adrenal hormones, with a focus on high-throughput testing for large clinical laboratories. Maccura’s reagents are designed to be compatible with its automated biochemical analyzers, enabling high-volume testing with minimal manual intervention. The company holds NMPA certifications for 60+ hormone reagents, and its products are used in 4,000+ hospitals across China, as well as exported to 30+ countries in Europe, Asia, and Africa. Maccura has invested heavily in quality control, implementing a full traceability system for raw materials and finished products, ensuring consistent reagent performance. In 2024, the company launched a new line of Fidx hormone reagents for precision medicine, tailored to individual patient profiles, supporting personalized treatment plans for hormone-related diseases. Maccura also provides training programs for clinical lab staff, ensuring proper use of its Fidx reagents and accurate test result interpretation.

Features and Advantages:

  • High-Throughput Compatibility: Fidx reagents optimized for high-volume automated analyzers, supporting up to 1,000 tests per hour, ideal for large clinical labs.
  • Extensive Certification: 60+ NMPA-certified reagents, plus ISO 13485 and CE, with a traceability system for every production batch.
  • Global Distribution: Exports to 30+ countries, with local warehouses in Germany and Singapore, reducing delivery times for international clients.
  • Precision Medicine Focus: Fidx reagents tailored for personalized hormone testing, supporting targeted treatment for cancer and fertility disorders.
  • Lab Support Services: Free training and technical support for 4,000+ domestic lab clients, ensuring optimal reagent performance.

5. Changchun Dazhong Biochemical Pharmaceutical Co., Ltd.

Company Introduction
Changchun Dazhong Biochemical Pharmaceutical Co., Ltd. is a specialized manufacturer of Fidx reagents for hormone testing, located in Changchun, Jilin Province, a key pharmaceutical hub in Northeast China. Founded in 1998, the company has 180 employees, including 50 R&D specialists, with a focus on raw material development and reagent formulation for hormone diagnostics. Dazhong Biochemical’s Fidx hormone reagents are primarily targeted at reproductive health testing, including FSH, LH, E2, and progesterone, with a reputation for high specificity and low cross-reactivity. The company’s production facility is GMP-certified, adhering to NMPA standards, and it has a 95% local market share in reproductive hormone Fidx reagents in Northeast China. Dazhong Biochemical invests in the development of monoclonal antibodies for hormone detection, a critical component of Fidx reagents, reducing reliance on imported raw materials. In 2025, the company launched a new line of Fidx reagents for anti-Müllerian hormone (AMH), a key marker for ovarian reserve, addressing growing demand from fertility clinics. Dazhong Biochemical also partners with the China Fertility Association to conduct clinical trials for its reagents, ensuring alignment with international reproductive health standards. The company’s focus on local supply chain development has made it a cost-effective supplier for regional hospitals and fertility centers.

Features and Advantages:

  • Reproductive Health Specialization: Leading supplier of Fidx reagents for 8 reproductive hormones, with 95% local market share in Northeast China.
  • Local Raw Material Development: In-house production of monoclonal antibodies for hormone detection, reducing costs and supply chain risks.
  • AMH Reagent Innovation: First Chinese supplier with NMPA certification for Fidx AMH reagents, a critical marker for female fertility assessment.
  • Clinical Collaboration: Partner with China Fertility Association, conducting 20+ clinical trials to validate reagent accuracy for reproductive testing.
  • Cost-Effectiveness: 20% lower pricing than imported Fidx hormone reagents, making it accessible to regional fertility clinics and hospitals.

6. Shanghai Kehua Bio-engineering Co., Ltd.

Company Introduction
Shanghai Kehua Bio-engineering Co., Ltd. is a prominent IVD company with a long history in diagnostic reagent development, including Fidx reagents for hormone testing. Established in 1991, Kehua is headquartered in Shanghai, with a production base spanning 60,000 square meters and an R&D team of 300 professionals. The company’s Fidx hormone reagent line covers 25+ hormone types, including thyroid, pituitary, and metabolic hormones, with a focus on both clinical and research applications. Kehua’s reagents are designed for compatibility with its own and third-party analyzers, offering flexibility for clinical labs. The company holds NMPA certifications for 55+ hormone reagents, and its products are used in 5,000+ hospitals across China, with exports to 25+ countries. Kehua has invested in digital health solutions, developing a cloud-based platform that integrates Fidx hormone test results with patient health records, enabling remote monitoring of hormone-related conditions. In 2025, the company launched a new line of Fidx hormone reagents for pediatric testing, optimized for small sample volumes, addressing a gap in the market for pediatric hormone diagnostics. Kehua also collaborates with the Chinese Academy of Sciences to advance Fidx technology, focusing on improving reagent stability for long-term storage.

Features and Advantages:

  • Wide Reagent Portfolio: 25+ hormone types, covering clinical and research needs, with compatibility for both in-house and third-party analyzers.
  • Digital Integration: Cloud-based platform linking Fidx test results to patient records, supporting remote monitoring of chronic hormone conditions.
  • Pediatric-Focused Reagents: Optimized Fidx reagents for small sample volumes, with a 98% accuracy rate for pediatric hormone testing.
  • Stability Innovation: Advanced formulation technology extending reagent shelf life to 24 months, reducing waste for clinical labs.
  • Large Domestic Client Base: 5,000+ hospital clients, with a national service network providing 24/7 technical support.

7. Guangzhou Wegene Biotechnology Co., Ltd.

Company Introduction
Guangzhou Wegene Biotechnology Co., Ltd. is a fast-growing Fidx reagent manufacturer specializing in hormone testing, located in Guangzhou, the commercial hub of South China. Founded in 2015, Wegene has a team of 100 R&D staff, including 25 PhDs, with expertise in fluorescent bead-based immunoassay technology, a core platform for multiplex Fidx hormone testing. The company’s product line focuses on multiplex hormone panels, enabling simultaneous detection of 6–8 hormones in a single sample, ideal for endocrinology and fertility testing. Wegene’s Fidx hormone reagents are certified by NMPA and CE, and are used in 1,500+ hospitals and research institutions across China, with exports to Southeast Asia and Australia. The company operates a 12,000-square-meter GMP facility, equipped with automated reagent packaging and quality control systems, ensuring high throughput and consistency. In 2024, Wegene launched a research-use-only (RUO) Fidx hormone panel for diabetes research, collaborating with leading Chinese diabetes centers to validate its performance. The company also invests in artificial intelligence (AI) for test result analysis, developing algorithms that interpret Fidx hormone data to identify potential hormone imbalances, supporting clinical decision-making. Wegene’s focus on multiplex technology has positioned it as a key player in the growing demand for comprehensive hormone testing solutions.

Features and Advantages:

  • Multiplex Panels: Detects 6–8 hormones in one sample, reducing testing time and sample volume, ideal for endocrinology and fertility clinics.
  • AI-Powered Analysis: AI algorithms that analyze Fidx hormone results to flag potential imbalances, assisting clinicians in diagnosis.
  • RUO Research Products: Specialized Fidx hormone panels for diabetes and cancer research, used by 50+ national research institutions in China.
  • Fast Growth: Exponential growth since 2020, with 1,500+ domestic clients and exports to 8 Asia-Pacific countries.
  • Flexible Customization: Tailored multiplex Fidx panels for specific research or clinical needs, with quick turnaround for product development.

8. Zhejiang Orient Gene Biotech Co., Ltd.

Company Introduction
Zhejiang Orient Gene Biotech Co., Ltd. is a global IVD manufacturer with a strong presence in Fidx reagents for hormone testing, based in Huzhou, Zhejiang Province. Founded in 2005, Orient Gene has two production bases totaling 100,000 square meters, and an R&D center with 220 scientists specializing in lateral flow and fluorescence immunoassay technologies. The company’s Fidx hormone reagents are primarily designed for POCT applications, with a focus on infectious disease and hormone testing for remote and resource-limited settings. Orient Gene’s hormone Fidx reagents include products for thyroid, pregnancy, and fertility testing, with over 30 NMPA certifications and 15 CE marks. The company exports to 120+ countries, making it one of the largest Chinese exporters of Fidx hormone reagents globally. In 2025, Orient Gene launched a new line of Fidx hormone reagents for COVID-19 recovery monitoring, measuring cortisol and thyroid hormone levels to assess post-viral effects. The company is committed to global health initiatives, donating Fidx hormone reagents to underserved regions in Africa and Southeast Asia. Orient Gene’s quality management system is certified by ISO 13485, FDA, and WHO prequalification, ensuring its products meet international standards for global distribution.

Features and Advantages:

  • Global Export Leader: Exports to 120+ countries, with WHO prequalification, making it a preferred supplier for global health programs.
  • POCT Specialization: Fidx reagents optimized for low-resource settings, with simple operation and no need for complex equipment.
  • Global Health Initiatives: Donated 2 million Fidx hormone reagent kits to underserved regions, supporting public health programs.
  • Wide Range of Certifications: ISO 13485, FDA, CE, and WHO prequalification, ensuring compliance for all major global markets.
  • Recovery Monitoring Products: Fidx reagents for post-viral hormone testing, addressing emerging needs for COVID-19 and other infectious disease recovery.

9. Jiangsu YHLO Biotech Co., Ltd.

Company Introduction
Jiangsu YHLO Biotech Co., Ltd. is a leading POCT IVD company, specializing in Fidx reagents for hormone and infectious disease testing, located in Suzhou, Jiangsu Province. Founded in 2011, YHLO has an R&D team of 180 professionals, including 40 PhDs, with expertise in fluorescence immunoassay and microfluidic technology. The company’s Fidx hormone reagent line includes products for thyroid, reproductive, and cardiac hormones, designed for use with its portable, point-of-care analyzers. YHLO’s reagents are certified by NMPA, CE, and FDA, and are used in 4,000+ hospitals and clinics across China, with exports to 40+ countries. The company’s production facility is 30,000 square meters, GMP-certified, with automated manufacturing lines ensuring high-volume production. In 2024, YHLO launched a new line of Fidx hormone reagents for at-home fertility testing, in partnership with global consumer health brands, expanding its reach to the consumer market. The company also invests in microfluidic technology, developing Fidx reagents that integrate sample processing and testing in a single device, further simplifying POCT workflows. YHLO’s focus on portability and ease of use has made its Fidx hormone reagents popular in remote and mobile healthcare settings, such as rural clinics and emergency response teams.

Features and Advantages:

  • Portable POCT Solutions: Fidx reagents compatible with handheld analyzers, ideal for rural clinics and mobile healthcare settings.
  • Consumer Market Expansion: At-home fertility Fidx reagents, sold via global e-commerce platforms, reaching 1 million consumers annually.
  • Microfluidic Integration: Fidx reagents with built-in sample processing, eliminating manual steps and reducing user error.
  • 4,000+ Domestic Clients: Strong presence in tier 2 and tier 3 hospitals, with local service teams in 20+ Chinese provinces.
  • Regulatory Approvals: NMPA, CE, and FDA clearances, enabling access to major markets in North America and Europe.

10. Beijing Strong Biotechnologies, Inc.

Company Introduction
Beijing Strong Biotechnologies, Inc. is a specialized Fidx reagent manufacturer for hormone testing, headquartered in Beijing’s Zhongguancun Science Park, a leading tech and life sciences cluster. Founded in 2008, Strong Bio has a team of 90 R&D staff, focusing on the development of high-sensitivity Fidx reagents for low-concentration hormone detection, a critical need for early disease diagnosis. The company’s product line includes Fidx reagents for thyroid-stimulating hormone (TSH), human chorionic gonadotropin (hCG), and luteinizing hormone (LH), with a detection limit as low to 0.0005 mIU/mL, among the lowest in China. Strong Bio operates a 8,000-square-meter GMP facility, certified by NMPA and ISO 13485, and its reagents are used in 1,200+ hospitals and research institutions across China, with exports to 10+ countries in Asia. The company collaborates with Peking University First Hospital to conduct clinical research on early thyroid cancer detection using its Fidx TSH reagents, validating their clinical utility. In 2025, Strong Bio launched a new line of Fidx hormone reagents for stress testing, measuring cortisol levels to support mental health diagnosis, addressing the growing demand for mental health-related diagnostic tools. The company’s focus on ultra-sensitive detection has positioned it as a key supplier for specialized clinical labs and research institutions.

Features and Advantages:

  • Ultra-Sensitive Detection: Lowest detection limit in China (0.0005 mIU/mL for TSH), enabling early diagnosis of hormone-related diseases.
  • Clinical Research Collaboration: Partner with Peking University First Hospital, conducting trials to validate reagents for early cancer detection.
  • Stress Testing Reagents: Fidx cortisol reagents for mental health diagnosis, addressing the emerging demand for mental health diagnostics.
  • Specialized Client Base: Preferred supplier for 1,200+ specialized clinical labs and research institutions, focusing on high-precision testing.
  • Niche Expertise: Specializes in low-concentration hormone detection, with a 90% market share in China’s ultra-sensitive Fidx hormone segment.

Incoag Reagents This article outlines the 10 leading Fidx reagents for hormone suppliers in China for 2026, highlighting their unique strengths, product portfolios, and market positions, reflecting the dynamic growth of China’s IVD sector in hormone diagnostics.